Skip to content
StackItSmart
BHuman cohort / observational

Milk Thistle

Silymarin

Milk thistle (Silybum marianum), standardized to its flavonolignan complex "silymarin" (chief active: silybin/silibinin), is a botanical hepatic-support supplement, not a drug and not a hormonal or performance agent. It is widely taken by people using androgens, oral 17-alpha-alkylated compounds, or other hepatotoxic substances in the belief it protects the liver, but this expectation outruns the evidence. Human data are abundant but of low and conflicting quality: meta-analyses of NAFLD/NASH RCTs show modest reductions in ALT/AST and improved steatosis, yet a rigorous NIH-funded RCT in hepatitis C found no benefit even at high doses, and Cochrane reviews found no reduction in all-cause mortality or complications for alcoholic/viral liver disease. Silymarin itself is remarkably well tolerated (adverse-event rates comparable to placebo), but the real danger is false reassurance. It does not neutralize the hepatotoxicity of anabolic steroids, alkylated orals, or alcohol, and taking it can delay someone from getting bloodwork and stopping a genuinely liver-damaging substance. It is an adjunct that must never replace lab monitoring or a clinician. Oral bioavailability is poor. The one setting with strong support is a different, intravenous formulation (silibinin) used in-hospital for Amanita mushroom poisoning, which does not translate to the oral supplement.

Clinical readoutAncillary · organ-support
Hepatic strainLow
CardiovascularNone
HPTA suppressionNone
Half-life
3.5 h
Route
Oral
Evidence
B
Active
Brief systemic exposure
3.5 h7 h10.5 h14 h17.5 h
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Short; oral silybin elimination half-life reported at roughly 1-6 hours, with rapid clearance.
Pharmacology

Mechanism of action

Silymarin is a mixture of flavonolignans (silybin A/B, isosilybin, silychristin, silydianin) plus taxifolin. Proposed hepatoprotective mechanisms are largely preclinical: free-radical scavenging and antioxidant activity, membrane stabilization of hepatocytes, stimulation of RNA polymerase I and ribosomal protein synthesis promoting hepatocyte regeneration, anti-inflammatory and antifibrotic effects (modulation of NF-kB, TGF-beta, stellate-cell activation), and, for silibinin specifically, competitive inhibition of the hepatic OATP uptake transporters that carry amatoxins into hepatocytes (the basis of its use in mushroom poisoning). It has no androgen, estrogen, or SERM activity and does not act on the hypothalamic-pituitary-gonadal axis.
Kinetics

Pharmacokinetics

Half-life

Short; oral silybin elimination half-life reported at roughly 1-6 hours, with rapid clearance.

Active duration

Brief systemic exposure; typically dosed 2-3 times daily in trials to maintain levels. Standardized oral products (e.g., Eurosil 85/silybin-phosphatidylcholine) are formulated to raise otherwise poor absorption.

Route

Oral (capsules/tablets standardized to ~70-80% silymarin) for supplement use; a separate water-soluble intravenous silibinin (silibinin dihemisuccinate) exists only for in-hospital treatment of amatoxin poisoning.

Metabolism & clearance

Poor oral bioavailability due to low aqueous solubility, low intestinal permeability, and extensive first-pass metabolism. Undergoes rapid phase II conjugation (glucuronidation and sulfation) and is eliminated substantially in bile/feces with enterohepatic recycling; a minor fraction renally excreted. Typical peak plasma silibinin concentrations are low (~0.2 microM); this profile matters for monitoring and drug-interaction assessment, not for evading any test.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Modest reduction in serum ALT and AST in pooled NAFLD/NASH RCTs (a biochemical, not clinical-outcome, effect)
  • Improvement in hepatic steatosis on histology/imaging and in fatty-liver indices in some NAFLD trials
  • Improvement in some lipid parameters (lower total cholesterol, triglycerides, LDL-C; higher HDL-C) and insulin-resistance markers in NAFLD meta-analysis
  • No effect on hepatitis C viral load, ALT normalization, or quality of life in a rigorous high-dose RCT
  • No demonstrated reduction in all-cause mortality or liver-disease complications in alcoholic/viral liver disease (Cochrane)
  • In-hospital intravenous silibinin is used adjunctively for Amanita phalloides (amatoxin) poisoning; this is a hospital treatment, not the oral supplement
  • Generally perceived hepatoprotective/antioxidant support; benefit is unproven for preventing drug- or steroid-induced liver injury
Safety

Adverse effects by system

Cardiovascular

No known cardiotoxicity. No adverse cardiovascular signal reported in human trials; some NAFLD data suggest neutral-to-favorable effects on lipids and insulin resistance rather than harm.

Hepatic

No hepatotoxicity signal; adverse-event rates were comparable to placebo in RCTs including doses up to 700 mg three times daily and Cochrane reviews found no increase in adverse events. Idiosyncratic liver injury attributable to milk thistle is not established. The real hepatic risk is indirect: false reassurance that may delay stopping a genuinely hepatotoxic agent.

Endocrine / HPTA

No hypothalamic-pituitary-gonadal (HPTA) activity; not a hormonal agent or SERM, so no testosterone suppression or stimulation is expected or reported. In people with diabetes, silymarin may lower blood glucose, which is a metabolic (not gonadal) effect and could compound hypoglycemic medication.

Reproductive

Insufficient human safety data in pregnancy and lactation; it has historically been used as a galactagogue but this is not a safety endorsement. No reported effect on fertility or reproductive hormones. Avoid in pregnancy/breastfeeding absent clinician guidance.

Neuropsychiatric

No known psychiatric or neuropsychiatric adverse effects reported.

Renal

No established nephrotoxicity; it has been studied as an adjunct in diabetic nephropathy without a clear renal-harm signal. No adequate human safety data specifically powered for renal outcomes in healthy users.

Hematologic

No known hematologic toxicity; no signal for cytopenias, polycythemia, or coagulation changes in human trials.

Dermatologic

Hypersensitivity/allergic skin reactions (rash, urticaria, pruritus) can occur, particularly in people allergic to the Asteraceae/Compositae family (ragweed, chrysanthemum, marigold, daisy). Rare.

Recovery

HPTA suppression & recovery

Suppression: None expected: not a hormonal agent

Milk thistle/silymarin has no androgenic, estrogenic, or SERM activity and does not suppress or stimulate the hypothalamic-pituitary-gonadal axis, so there is no HPTA suppression to recover from. It is not a substitute for, and plays no role in, post-cycle or fertility recovery; single-SERM frameworks and dual-SERM protocols are irrelevant here and dual-SERM use is never endorsed. Any concern about testosterone suppression or HPTA recovery from other compounds should be directed to an endocrinologist and guided by hormonal bloodwork, not by taking an organ-support supplement.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Liver function tests (ALT, AST, ALP, bilirubin), baseline and periodically, driven by the underlying reason for liver concern rather than by the supplement itselfFasting glucose / HbA1c if diabetic or on glucose-lowering therapyLipid panel if being taken in the context of metabolic/fatty liver diseaseGGT where alcohol or other hepatotoxin exposure is a concern

Cadence: Baseline before starting; if used alongside any hepatotoxic substance (e.g., alkylated orals, high alcohol intake), recheck LFTs roughly every 4-8 weeks and promptly if symptomatic. In stable supplement use, align labs with routine clinician follow-up.

Warning signs — seek care
  • Signs of allergic reaction: rash, hives, itching, facial/throat swelling, wheezing. Stop and seek care
  • New or worsening jaundice (yellow skin/eyes), dark urine, pale stools, right-upper-quadrant pain. Seek urgent medical evaluation; do not rely on the supplement
  • Persistent nausea, vomiting, bloating, or diarrhea (mild GI/laxative effects are the most common complaints)
  • Symptoms of low blood sugar (shakiness, sweating, confusion) in people on glucose-lowering drugs
  • Any rising liver enzymes despite the supplement: a signal to investigate and stop the offending agent, not to increase the supplement
Do not use if

Contraindications

  • Known hypersensitivity to Silybum marianum or the Asteraceae/Compositae family (ragweed, chrysanthemums, marigolds, daisies)
  • Pregnancy and breastfeeding: insufficient human safety data
  • Diabetes or use of insulin/sulfonylureas/other hypoglycemics: additive blood-glucose lowering possible; monitor glucose
  • Do not use as a replacement for medical evaluation in acute liver injury, jaundice, or suspected drug/steroid-induced hepatotoxicity; these require a clinician
  • Caution with narrow-therapeutic-index drugs cleared by glucuronidation or CYP2C9/2C19/2D6/3A4 at very high supplement doses (clinically significant interaction unlikely at usual exposure but not excluded)
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Do not treat milk thistle as liver protection that lets you continue a hepatotoxic substance (alkylated oral steroids, heavy alcohol, other hepatotoxins). Human evidence does not show it prevents or reverses that damage; the safest action for a stressed liver is to stop the offending agent and get evaluated.
  • Get baseline and periodic liver bloodwork (ALT, AST, ALP, bilirubin) through a clinician rather than relying on how you feel; early liver injury is often asymptomatic.
  • Stop immediately and seek urgent care for jaundice, dark urine, pale stools, severe right-upper-quadrant pain, or signs of an allergic reaction (hives, swelling, wheezing).
  • If you have ragweed/daisy/chrysanthemum/marigold allergy, avoid it due to Asteraceae cross-reactivity.
  • If you have diabetes or take glucose-lowering medication, monitor blood sugar, since silymarin may lower glucose.
  • Avoid in pregnancy and breastfeeding because human safety data are inadequate.
  • Choose the reason to stop over the reason to continue: rising liver enzymes are a signal to investigate and discontinue the causative agent, never to escalate the supplement.
  • Discuss any supplement with the clinician managing your liver, especially if you take narrow-therapeutic-index medications, and never let it substitute for prescribed treatment or specialist care.
Evidence

Citations (11)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    Silymarin is the flavonolignan extract of milk thistle with silybin/silibinin as the main active constituent; poor oral bioavailability due to low solubility, low permeability, and rapid metabolism, with peak plasma silibinin ~0.2 microM.

    ReviewPMID 21951025 ↗

  2. 02

    Milk thistle chemistry, pharmacokinetics, phase II conjugation and biliary elimination, and clinical uses across alcoholic liver disease, NAFLD, viral hepatitis, drug-induced injury, and mushroom poisoning; encouraging preclinical data but need for better RCTs.

    ReviewDOI 10.1002/ptr.6171 ↗

  3. 03

    Meta-analysis of 26 RCTs (2,375 patients): silymarin significantly reduced ALT and AST, improved lipid parameters and insulin-resistance markers, and improved hepatic steatosis on histology in NAFLD/NASH, with authors noting effects require further confirmation.

    Meta-analysisDOI 10.1016/j.aohep.2023.101174 ↗

  4. 04

    Systematic review/meta-analysis of dietary polyphenols in NAFLD: silymarin was effective in improving ALT and AST and reducing hepatic fat accumulation and liver stiffness, but more RCTs are needed.

    Meta-analysisDOI 10.3389/fimmu.2022.949746 ↗

  5. 05

    In a multicenter, double-blind, placebo-controlled RCT (n=154) of chronic hepatitis C unresponsive to interferon, oral silymarin at 420 mg or 700 mg three times daily for 24 weeks did not reduce ALT or HCV RNA more than placebo, and its adverse-event profile was comparable to placebo.

    RCTDOI 10.1001/jama.2012.8265 ↗

  6. 06

    Cochrane review of 18 RCTs (1,088 patients) in alcoholic and/or hepatitis B/C liver disease: milk thistle had no significant effect on all-cause mortality, complications, or histology, and was not associated with increased adverse events; overall low methodological quality.

    Meta-analysisDOI 10.1002/14651858.CD003620.pub3 ↗

  7. 07

    Cochrane network meta-analysis of pharmacological interventions for NAFLD (77 trials): evidence for antioxidants/agents including silymarin is very low quality, with uncertainty about effectiveness.

    Meta-analysisDOI 10.1002/14651858.CD011640.pub2 ↗

  8. 08

    Silymarin is generally very well tolerated with a low incidence of adverse events and no treatment-related serious adverse events in clinical trials; a pooled analysis in cirrhosis suggested reduced liver-related deaths, and standardized formulations improve oral bioavailability.

    ReviewDOI 10.1007/s12325-020-01251-y ↗

  9. 09

    In vitro drug-interaction assessment: silymarin did not induce CYP2C9/3A4 and inhibited major CYP enzymes only at high concentrations (>50% inhibition at 100 microM); at clinically relevant plasma silibinin (~0.2 microM) no meaningful drug-drug interaction is expected.

    PreclinicalDOI 10.1016/j.tiv.2007.11.020 ↗

  10. 10

    Small triple-blind placebo-controlled RCT (n=30) in breast-cancer patients on AC-T chemotherapy: oral silymarin 140 mg three times daily reduced ultrasonographic hepatotoxicity severity, though FibroScan and liver function tests did not differ between groups.

    RCTDOI 10.1177/10781552211006182 ↗

  11. 11

    Intravenous silibinin is used adjunctively in hospital management of Amanita phalloides (amatoxin) mushroom poisoning; no definitive antidote exists and this parenteral use is distinct from the oral supplement.

    ReviewDOI 10.1093/gastro/gov062 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice